Clinical Research Directory
Browse clinical research sites, groups, and studies.
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
Sponsor: David Wilson
Summary
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
Official title: First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in the Brains of Healthy Controls and Patients With Dementia.
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2021-11-02
Completion Date
2027-05-31
Last Updated
2025-04-17
Healthy Volunteers
Yes
Interventions
[18F]RP-115 PET/MRI or PET/CT and MRI
An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
Locations (1)
China Basin, UCSF
San Francisco, California, United States